BioVie Inc. (NASDAQ:BIVI) Short Interest Update

BioVie Inc. (NASDAQ:BIVI) was the recipient of a significant decrease in short interest in November. As of November 15th, there was short interest totalling 1,350,000 shares, a decrease of 29.7% from the October 31st total of 1,920,000 shares. Currently, 19.6% of the shares of the stock are sold short. Based on an average daily volume of 5,610,000 shares, the short-interest ratio is presently 0.2 days.

BioVie Stock Up 3.3 %

BIVI traded up $0.09 during midday trading on Friday, reaching $2.80. 1,098,797 shares of the company’s stock were exchanged, compared to its average volume of 1,691,573. The business has a 50-day simple moving average of $2.27 and a two-hundred day simple moving average of $1.64. The firm has a market capitalization of $49.76 million, a price-to-earnings ratio of -0.24 and a beta of 0.40. BioVie has a one year low of $1.04 and a one year high of $33.10.

BioVie (NASDAQ:BIVI) last posted its earnings results on Monday, September 30th. The company reported ($6.60) EPS for the quarter.

About BioVie

BioVie Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease.